Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Oct 15, 2026; 18(10): 121827
Published online Oct 15, 2026. doi: 10.4251/wjgo.121827
Published online Oct 15, 2026. doi: 10.4251/wjgo.121827
Figure 7 In vivo validation of the effects of PARVA and FBXO15 on gastric cancer growth and PI3K/AKT pathway activation.
A: Representative images of nude mice and subcutaneous xenograft tumors from each group; B: Tumor weight and final tumor volume in each group; C: Immunohistochemical staining of p-PI3K, p-AKT, and Ki67 in xenograft tissues; D: Quantitative analysis of p-PI3K, p-AKT, and Ki67 staining. aP < 0.001. NC: Negative control; Pa: PARVA; Fb: FBXO15.
- Citation: Lu X, Li J, Wang ML, Wang HZ, Li YX. PARVA promotes gastric cancer progression through FBXO15-related PI3K/AKT signaling. World J Gastrointest Oncol 2026; 18(10): 121827
- URL: https://www.wjgnet.com/1948-5204/full/v18/i10/121827.htm
- DOI: https://dx.doi.org/10.4251/wjgo.121827